CALLABLE MULTI DEFENDER VONTI - NOVO-NORDISK B/ELI LILLY & CO | Market Closed - Swiss Exchange 11:20:00 2024-05-16 am EDT | ||
| 103.3 CHF | +0.10% |
|
| Current month | +0.49% | ||
| 3 months | -0.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-16 | 103.3 | +0.10% |
| 24-05-10 | 103.2 | +0.19% |
| 24-05-08 | 103 | +0.10% |
Delayed Quote Swiss Exchange
Last update May 16, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| RMASBV | |
| ISIN | CH1283320989 |
| Date issued | 2023-09-01 |
| Strike | 557.1 $ |
| Maturity | 2025-03-03 (290 Days) |
| Parity | 1 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | both |
| Currency | CHF |
Technical Indicators
| Highest since issue | 104.2 CHF |
|---|---|
| Lowest since issue | 97.5 CHF |
| Spread | 8 CHF |
| Spread % | 0.77% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- RMASBV Certificat